What’s Up with U.S. Merger Remedies? A Podcast Episode Featuring Jeny Maier
February 26, 2024, 3:14 PM
By: Axinn Insights
The US antitrust agencies’ approach to merger remedies has undergone a significant change under the Biden administration. Remedies are increasingly disfavored.
Axinn's Managing Partner Jeny Maier joins Dan Ducore, former Assistant Director of the Federal Trade Commission’s Bureau of Competition Compliance Division, and co-host Barry Nigro on Our Curious Amalgam to discuss the growing skepticism towards merger remedies by the US antitrust authorities.
Listen to this episode to learn more about whether merger remedies remain a viable option in the US and, if so, how parties should approach them given the government’s current hostility toward remedies.
To subscribe to our publications, click here.
Tags
News & Insights
News & Insights
ACI Forum on Pharma & Biotech Patent Litigation USA 2025
Speaking Engagement
Intellectual Property
CCWC 21st Annual Career Strategies Conference
Speaking Engagement
Fordham 52nd Annual Conference on International Antitrust Law and Policy
Speaking Engagement
Antitrust
Kisaco Research Trade Secret Legal Protection Conference 2025
Speaking Engagement
Intellectual Property
SCCE 23rd Annual Compliance & Ethics Institute
Speaking Engagement
Antitrust
29th Annual IBA Competition Conference
Sponsorship
Antitrust
Key Appellate Decisions Shaping Antitrust Strategy
Webinar
Antitrust
New Frontiers of Antitrust – 16th Annual International Conference of Concurrences Review
Speaking Engagement
Antitrust
MCCA Pathways Conference
Sponsorship
Antitrust
HNBA/VIA Annual Convention 2025
Sponsorship
Antitrust